Heritage Wealth Advisors Sells 2,988 Shares of Pfizer Inc. $PFE

Heritage Wealth Advisors decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 38.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,746 shares of the biopharmaceutical company’s stock after selling 2,988 shares during the quarter. Heritage Wealth Advisors’ holdings in Pfizer were worth $115,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Westbourne Investments Inc. bought a new stake in shares of Pfizer in the 1st quarter worth about $2,411,000. Bourne Lent Asset Management Inc. raised its holdings in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares during the period. Strs Ohio bought a new stake in shares of Pfizer during the first quarter worth $49,968,000. IFM Investors Pty Ltd lifted its holdings in Pfizer by 3.8% during the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after buying an additional 41,263 shares in the last quarter. Finally, Intrua Financial LLC raised its stake in shares of Pfizer by 17.4% during the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after acquiring an additional 11,643 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $25.45 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $144.70 billion, a PE ratio of 13.54, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The business’s fifty day simple moving average is $24.82 and its 200-day simple moving average is $24.46.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PFE shares. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.